Exact Sciences Corporation (EXAS) Bounced Back in Q3
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
Exact Sciences Corp (EXAS)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 227,444 | $15,493,496 | -34% | 0.14% |
| 2. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 57,818 | $3,938,562 | -4% | 1.49% |
| 3. | Skylands Capital Charles Paquelet | 400 | $27,248 | -97% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.71 | 2,500 | Director | 60,858 | 2017-08-17 | Filing | |
| $13.84 | 10,000 | Director | 136,379 | 2016-12-14 | Filing | |
| $18.10 | 5,000 | Director | 121,247 | 2016-09-01 | Filing | |
| $17.93 | 3,380 | Director | 105,927 | 2016-08-03 | Filing | |
| $5.38 | 3,775 | Director | 91,000 | 2016-03-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $70.00 | 929 | 12,758 | 2024-10-08 | Filing | ||
| $70.00 | 929 | 13,687 | 2024-09-18 | Filing | ||
| $60.15 | 67 | 44,644 | 2024-05-01 | Filing | ||
| $60.15 | 136 | 47,042 | 2024-05-01 | Filing | ||
| $60.15 | 30 | 9,866 | 2024-05-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,559,751 | $1,299,070,379 | 0.02% | |
| 2. | 16,690,808 | $1,234,786,033 | 0.13% | |
| 3. | 11,053,013 | $817,701,874 | 0.02% | |
| 4. | 10,280,814 | $760,574,619 | 0.14% | |
| 5. | 7,468,145 | $552,493,367 | 0.09% |
News See All
10 Buzzing AI Health Stocks
The economic impact of AI is projected to be substantial, particularly in regions like China and North America, which are expected to see GDP boosts of 26% and 14.5%, respectively, by 2030, amounting ...
Should You Hold Exact Sciences Corporation (EXAS)?
Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its second quarter 2024 investor letter. A copy of the fund can be downloaded here.
Should You Believe in the Growth Potential of Exact Sciences Corporation (EXAS)?
Baron Funds, an investment management company, released its “Baron Discovery Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Here’s Why Baron Opportunity Fund Sold its Stake in Exact Sciences Corp (EXAS)
Baron Funds, an investment management company, released its “Baron Opportunity Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Exact Sciences Corporation (NASDAQ:EXAS) Q2 2024 Earnings Call Transcript
Operator: Thank you for standing by. At this time, I would like to welcome everyone to today's Exact Sciences Second Quarter 2024 Earnings Call.
Exact Sciences Corporation (EXAS) Slipped Over Investors’ Concerns
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Is Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Exact Sciences Corporation (NASDAQ:EXAS) is the gene therapy stock with the greatest potential...
9 Best Gene Therapy Stocks to Buy Now
In this article, we will be discussing the best gene therapy stocks to buy now. Before we move on to our list, let's take a look at the market outlook for gene therapies and understand the reasons behind...
Hedge Funds are Bullish on This Cancer Stock
The healthcare industry is considered to be a fairly defensive sector due to its need.